Product Images Oxcarbazepine

Oxcarbazepine is a prescription medication available in a quantity of 100 HD2 tablets. The medication is only available with a prescription. The National Drug Code (NDC) for this product is 70518-1980-01 and the manufacturer is Sun Pharma from Dadra, India. The expiration date and lot number are not available. The medication should be kept away from children, and the package insert should be followed for directions for use. The medication should be stored between 20-26°C (63-77°F) with permitted excursions to 15-30°C (59-86°F) according to USP. The product has been repackaged by RemedyRepack Inc. from Indiana, PA.*

OXcarbazepine is a prescription medication manufactured by Sun Pharma in Dadra, India. It is available in a bottle containing one HD2. The medicine is not intended for minors, so keep it away from children. The package comes with instructions, and it should be stored at a temperature of 20 to 26°C. The RemedyRepack Inc. has repackaged it in Indiana, PA. The Lot number and expires date are missing.*

This is a medication called OXcarbazepine, available in a quantity of 30 HD2 units and is a prescription drug. The product is re-packaged by RemedyRepack Inc., Indiana, PA 15701, with the manufacturing source located in Sun Pharma, Dadra, India 396 191. It contains directions for use in the package insert and should be stored between 20-26°C (63-77°F), with excursions allowed to 15-30°C (59-86°F). The lot number is not available, and it is important to keep this and all medications out of reach of children. NDC# is 70518-1980-00. It also bears the legend "Rx Only".*

This appears to be a figure depicting Kaplan-Meier estimates of exit rate by treatment group. The graph shows the exit rate over time for the treatment groups of Oxcarbazepine and Placebo. The log-rank test P-value is 0.0001. The X-axis shows the time on trial (in days), ranging from Day 2 to Day 11. The Y-axis shows the exit rate.*

The figure 3 shows Kaplan-Meier Estimates of Exit Rate by Treatment Group over the course of days. The graph displays two groups, HIGH and LOW, and their relative exit rates over 130 days. The log-rank test resulted in a significant p-value of 0.0001.*

This text presents data analysis results on the "Exit rate" by Treatment Group, as shown in Figure 4, using the Kaplan-Meier Estimates method. The log-rank test with a p-value of 0.0001 was used to evaluate the results. However, the last line of the text contains non-readable characters, making it difficult to provide a complete conclusion.*